MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers.

BACKGROUND Among biomarkers, cancer-antigen 125 (CA-125) is the most studied. We propose an analytical tool to track ovarian carcinoma biomarkers, that is, the MALDI mass spectrometry imaging. MATERIAL/METHODS Ovarian carcinomas and benign ovaries were directly analyzed by MALDI-TOF-MS. After automatic profiling and mass spectrometry imaging analyses, hierarchical clustering based on principal component analysis in nonsupervised mode was carried out. On the same samples, preparations were performed to investigate peptides, then proteins, followed by high mass proteins, in an automatic profiling to specific signatures for diagnosis. Using tissue bottom-up strategy on tissue digestion, and mass spectrometry imaging after by shotgun sequencing by nalano-LC-IT-MS in MS/MS mode from washing samples from on tissue digested peptides, several biomarkers were found. RESULTS A list of specific biomarkers from the ovarian carcinoma regions was obtained and classified as proteins associated with cell proliferation, involved in immune response modulation, signaling to the cytoskeleton, and tumor progression. These specific biomarkers were then validated by immunocytochemistry using Tag-mass technology, cell biology, Western blot, and by PCR (using SKOV-3 ovarian epithelial cancer cells). A link between the immune regulation (innate immunity, tolerance) and virus cause is also discussed. CONCLUSIONS From the biomarkers identified, proteins involved in immune response modulation and cell proliferation have been pointed out in this study. Two new markers have been identified using such a strategy, that is, fragment C-terminal of the PSME1 (Reg-Alpha) and mucin-9.

[1]  I. Fournier,et al.  MALDI mass spectrometry imaging of proteins exceeding 30,000 daltons. , 2010, Medical science monitor : international medical journal of experimental and clinical research.

[2]  Michel Salzet,et al.  Epithelial-mesenchymal transition in ovarian cancer. , 2010, Cancer letters.

[3]  I. Fournier,et al.  Improving tissue preparation for matrix-assisted laser desorption ionization mass spectrometry imaging. Part 1: using microspotting. , 2009, Analytical chemistry.

[4]  J. Cavaillon,et al.  Hemopexin down‐regulates LPS‐induced proinflammatory cytokines from macrophages , 2009, Journal of leukocyte biology.

[5]  R. Bristow,et al.  Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. , 2009, Anticancer research.

[6]  J. Pfeilschifter,et al.  Biglycan, a Danger Signal That Activates the NLRP3 Inflammasome via Toll-like and P2X Receptors* , 2009, The Journal of Biological Chemistry.

[7]  D. Fremont,et al.  T-Cell Tolerance for Variability in an HLA Class I-Presented Influenza A Virus Epitope , 2009, Journal of Virology.

[8]  M. Birrer,et al.  Validation of serum biomarkers for detection of early-stage ovarian cancer. , 2009, American journal of obstetrics and gynecology.

[9]  T. Jardetzky,et al.  Cleavage and Secretion of Epstein-Barr Virus Glycoprotein 42 Promote Membrane Fusion with B Lymphocytes , 2009, Journal of Virology.

[10]  R. Longnecker,et al.  Cleavage of Epstein-Barr virus glycoprotein B is required for full function in cell-cell fusion with both epithelial and B cells. , 2009, The Journal of general virology.

[11]  Sören-Oliver Deininger,et al.  MALDI imaging combined with hierarchical clustering as a new tool for the interpretation of complex human cancers. , 2008, Journal of proteome research.

[12]  Sandra Rauser,et al.  MALDI imaging mass spectrometry for direct tissue analysis: a new frontier for molecular histology , 2008, Histochemistry and Cell Biology.

[13]  Patrick Ducoroy,et al.  Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. , 2007, Journal of proteome research.

[14]  G. Rice,et al.  Neutrophil gelatinase‐associated lipocalin (NGAL) an early‐screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor‐induced epithelio‐mesenchymal transition , 2007, International journal of cancer.

[15]  I. Fournier,et al.  Tag-mass: specific molecular imaging of transcriptome and proteome by mass spectrometry based on photocleavable tag. , 2007, Journal of proteome research.

[16]  Cristina Al-Khalili Szigyarto,et al.  Large-scale proteomics analysis of human ovarian cancer for biomarkers. , 2007, Journal of proteome research.

[17]  Kathleen R. Cho,et al.  Classifications of ovarian cancer tissues by proteomic patterns , 2006, Proteomics.

[18]  I. Konishi,et al.  Nuclear expression of S100A4 is associated with aggressive behavior of epithelial ovarian carcinoma: An important autocrine/paracrine factor in tumor progression , 2006, Cancer science.

[19]  I. Fournier,et al.  MALDI-MS direct tissue analysis of proteins: Improving signal sensitivity using organic treatments. , 2006, Analytical chemistry.

[20]  A. Holle,et al.  Optimizing UV laser focus profiles for improved MALDI performance. , 2006, Journal of mass spectrometry : JMS.

[21]  Marie-Christine W. Gast,et al.  Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. , 2006, Trends in pharmacological sciences.

[22]  Gilbert S Omenn,et al.  Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. , 2006, Journal of proteome research.

[23]  P. Collinet,et al.  Tumeurs de l'ovaire et CA 125 en 2006 , 2006 .

[24]  M. Fields,et al.  Ovarian cancer screening: a look at the evidence. , 2006, Clinical journal of oncology nursing.

[25]  I. Fournier,et al.  Solid ionic matrixes for direct tissue analysis and MALDI imaging. , 2006, Analytical chemistry.

[26]  Kwang Dong Kim,et al.  Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. , 2005, Biochemical and biophysical research communications.

[27]  U. Puistola,et al.  Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. , 2005, Gynecologic oncology.

[28]  Florian J Schweigert,et al.  Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients , 2005, BMC Cancer.

[29]  Deborah Schrag,et al.  Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. , 2005, Journal of the National Cancer Institute.

[30]  Marian F Young,et al.  The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. , 2005, The Journal of clinical investigation.

[31]  Xiao-Ying Meng,et al.  Classification of cancer types by measuring variants of host response proteins using SELDI serum assays , 2005, International journal of cancer.

[32]  F. Schweigert.  Characterisation of protein microheterogeneity and protein complexes using on-chip immunoaffinity purification-mass spectrometry. , 2005, Briefings in functional genomics & proteomics.

[33]  A. Rickinson,et al.  CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells , 2005, The Journal of experimental medicine.

[34]  Timothy D. Veenstra,et al.  Proteomic patterns: their potential for disease diagnosis , 2005, Molecular and Cellular Endocrinology.

[35]  P. Leung,et al.  Gain of OGP, an Estrogen-Regulated Oviduct-Specific Glycoprotein, Is Associated with the Development of Endometrial Hyperplasia and Endometrial Cancer , 2004, Clinical Cancer Research.

[36]  E. Petricoin,et al.  Biomarkers of ovarian tumours. , 2004, European journal of cancer.

[37]  Amy P N Skubitz,et al.  Differential gene expression in ovarian carcinoma: identification of potential biomarkers. , 2004, The American journal of pathology.

[38]  H. R. Bergen,et al.  Discovery of Ovarian Cancer Biomarkers in Serum Using NanoLC Electrospray Ionization TOF and FT-ICR Mass Spectrometry , 2004, Disease markers.

[39]  M. Sakaguchi,et al.  Introduction of an N-terminal peptide of S100C/A11 into human cells induces apoptotic cell death , 2004, Journal of Molecular Medicine.

[40]  Stanimire Tomov,et al.  Clinical Proteomics and Biomarker Discovery , 2004, Annals of the New York Academy of Sciences.

[41]  E. Petricoin,et al.  High-resolution serum proteomic features for ovarian cancer detection. , 2004, Endocrine-related cancer.

[42]  P. Leung,et al.  Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts. , 2004, Gynecologic oncology.

[43]  S. Kjaer,et al.  The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. , 2004, Anticancer research.

[44]  M. Sakaguchi,et al.  PKCα mediates TGFβ-induced growth inhibition of human keratinocytes via phosphorylation of S100C/A11 , 2004, The Journal of cell biology.

[45]  G. Yousef,et al.  Immunofluorometric Quantification of Human Kallikrein 5 Expression in Ovarian Cancer Cytosols and Its Association with Unfavorable Patient Prognosis , 2003, Tumor Biology.

[46]  E. Kohn,et al.  Promising directions for the diagnosis and management of gynecological cancers , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[47]  Ming Zhou,et al.  Cancer diagnosis using proteomic patterns , 2003, Expert review of molecular diagnostics.

[48]  S. Mok,et al.  Expression of cytokines and receptors in normal, immortalized, and malignant ovarian epithelial cell lines. , 2003, Anticancer research.

[49]  E. Fung,et al.  Proteomic approaches to tumor marker discovery. , 2002, Archives of pathology & laboratory medicine.

[50]  Douglas C Pearl,et al.  Proteomic patterns in serum and identification of ovarian cancer , 2002, The Lancet.

[51]  M. Elwood.  Proteomic patterns in serum and identification of ovarian cancer , 2002, The Lancet.

[52]  E. Petricoin,et al.  Clinical potential of proteomics in the diagnosis of ovarian cancer , 2002, Expert review of molecular diagnostics.

[53]  Ulrich Steinhoff,et al.  Link between Organ-specific Antigen Processing by 20S Proteasomes and CD8+ T Cell–mediated Autoimmunity , 2002, The Journal of experimental medicine.

[54]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[55]  T. Giese,et al.  Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. , 2001, European journal of immunology.

[56]  P. Pandolfi,et al.  PML mediates the interferon‐induced antiviral state against a complex retrovirus via its association with the viral transactivator , 2001, The EMBO journal.

[57]  Tony S. Tao,et al.  Proinflammatory properties of the human S100 protein S100A12 , 2001, Journal of leukocyte biology.

[58]  A. Capron,et al.  Molecular crosstalk in host-parasite relationships: schistosome- and leech-host interactions. , 2000, Parasitology today.

[59]  B. No̸rgaard-Pedersen,et al.  The prognostic value of pretherapeutic tetranectin and CA-125 in patients with relapse of ovarian cancer. , 2000, Gynecologic oncology.

[60]  R. Bast,et al.  Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass , 2000 .

[61]  L C Murphy,et al.  Lumican and decorin are differentially expressed in human breast carcinoma , 2000, The Journal of pathology.

[62]  A. Rivett,et al.  Proteasome inhibitors: from in vitro uses to clinical trials , 2000, Journal of peptide science : an official publication of the European Peptide Society.

[63]  C. Høgdall,et al.  Serum tetranectin and CA125 in endometrial adenocarcinoma. , 2000, Anticancer research.

[64]  B. Seliger,et al.  Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin , 2000, Bone Marrow Transplantation.

[65]  Kloetzel Pm.  The proteasome system: a neglected tool for improvement of novel therapeutic strategies? , 1998 .

[66]  N. Brünner,et al.  The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. , 1998, Cancer research.

[67]  L. Murphy,et al.  Expression of lumican in human breast carcinoma. , 1998, Cancer research.

[68]  L. Twiggs,et al.  α‐1 acid glycoprotein is an immunosuppressive factor found in ascites from ovarian carcinoma , 1997 .

[69]  M. Monden,et al.  Epithelial‐mesenchymal transformation of a newly established cell line from ovarian adenosarcoma by transforming growth factor‐B1 , 1996 .

[70]  P. Kloetzel,et al.  LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12 , 1996, The Journal of experimental medicine.

[71]  P. A. Peterson,et al.  In Vivo Assembly of the Proteasomal Complexes, Implications for Antigen Processing (*) , 1995, The Journal of Biological Chemistry.

[72]  F. Jänicke,et al.  A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. , 1993, The Journal of clinical investigation.

[73]  A. Ignatchenko,et al.  A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. , 2008, Journal of proteome research.

[74]  D. Vinatier,et al.  [Ovarian cancers and CA 125 in 2006]. , 2006, Gynecologie, obstetrique & fertilite.

[75]  R. Bast,et al.  Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. , 2000, International journal of cancer.

[76]  P. Kloetzel.  The proteasome system: a neglected tool for improvement of novel therapeutic strategies? , 1998, Gene Therapy.

[77]  L. Twiggs,et al.  Alpha-1 acid glycoprotein is an immunosuppressive factor found in ascites from ovaria carcinoma. , 1997, Cancer.